Mary Thanh Hai - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Filters

Mary Thanh Hai

Showing results (1-10 of 4) with videos related to

Pageof 1

Sort By:

JAMA|August 21, 2024

Surrogate Markers and Clinical OutcomesJeffrey Siegel, Mary Thanh Hai, Peter Stein

The New England Journal of Medicine|September 23, 2020

Assessing the Safety of Glucose-Lowering Drugs - A New Focus for the FDAWilliam H Chong, Lisa B Yanoff, Eugenio Andraca-Carrera, et al.

Clinical Pharmacology and Therapeutics|September 1, 2025

Analysis by Age, Sex, Race, and Ethnicity of Participants in Clinical Trials Supporting Recently Approved Novel TherapiesNeali H Lucas, Jinzhong Liu, Aden Asefa, et al.

Annals of Internal Medicine|October 14, 2024

Opportunities for Innovation in Smoking Cessation Therapies: A Perspective From the National Institutes of Health and U.S. Food and Drug AdministrationHaider J Warraich, Brian A King, Wilson M Compton, et al.

Pageof 1

Search research articles

Showing results (1-10 of 4) with videos related to

Sort By:

Pageof 1

JAMA|August 21, 2024

Surrogate Markers and Clinical OutcomesJeffrey Siegel, Mary Thanh Hai, Peter Stein

The New England Journal of Medicine|September 23, 2020

Assessing the Safety of Glucose-Lowering Drugs - A New Focus for the FDAWilliam H Chong, Lisa B Yanoff, Eugenio Andraca-Carrera, et al.

Clinical Pharmacology and Therapeutics|September 1, 2025

Analysis by Age, Sex, Race, and Ethnicity of Participants in Clinical Trials Supporting Recently Approved Novel TherapiesNeali H Lucas, Jinzhong Liu, Aden Asefa, et al.

Annals of Internal Medicine|October 14, 2024

Opportunities for Innovation in Smoking Cessation Therapies: A Perspective From the National Institutes of Health and U.S. Food and Drug AdministrationHaider J Warraich, Brian A King, Wilson M Compton, et al.

Pageof 1